tv Nightly Business Report PBS December 1, 2015 6:30pm-7:01pm PST
. this is "nightly business report" with tyler mathisen and sue herara. >> december to remember? the month that's usually kind to investors got off to a strong start. >> hitting the gas. what the u.s. auto industry did today that it's never done before. and out of reach. why some patients have a difficult time getting access to certain drugs, just when this he need them the most. all that and more tonight on "nightly business report" for tuesday, december 1st. good evening, everyone. welcome. december is here, and the calendar is on your side. the month that's historically good to stock investors got off to a strong start, shaking off weak manufacturing data and focusing instead on strong sales in the auto industry. as investors hope to stretch the market's win streak to three straight months.
today, the major averages all gained about 1%. the dow jones industrial average rose 168 points to 17,888. the nasdaq added 47 and the s&p 500 was up 22 to close above the psychologically important 2100 level. bob pisani has more on the sectors that tend to do well in the final month of the year. >> reporter: historically, december is the best month for the s&p 500. in the last 25 years, the s&p 500 has been up 80% of the time in december for an average gain of nearly 2%. that's according to data from kin show. what's less commonly known is the sector performance is uneven. according to ken show again, the best performing sector in december for the last 25 years has been industrials up 84% of the time for an average gain of almost 3%. another surprise, utilities was the second biggest gainer. oddly the sector that gets the biggest publicity in december, technology stocks, they're only up about half the time.
why is that? the data doesn't tell us, but it's possible investors are still unsure about the capital spending plans of companies and since technology is where a lot of the capital spending occurs, investors just fear the worst. for "nightly business report," i'm bob pisani at the new york stock exchange. more now on the hot november auto sales. the results show the american consumer is not slowing down spending on new cars, trucks and suvs. in fact, the annualized is sales pace climbed above 18 million vehicles for the third straight month, something that has never happened before in the u.s. as phil lebeau reports, it was a very good month for every automaker with one notable exceptionings. >> year end promotions offering slightly greater discounts kept auto sales moving at a near record pace last month. toyota led the largest automakers in terms of sales gains. but all of them had a solid november thanks to strong demand for bigger, more expensive pickups and suvs.
jeep sales surged 20%. while ford truck sales were up almost as much. >> we're seeing strong demand for the f series truck. we had a strong month in november of sales again. we're predicting increased sales over the next couple years. >> ford is hiring another 2,000 workers to expand production of its f series super duty pickups. overall, low interest rates and high consumer confidence are convincing many this is the time to buy. and when they do, they're opting for trucks and suvs. because gas prices are so low, fuel efficiency is not a priority. >> momentum in the last three months, we believe because people are starting to accept that gas prices are going to be lower for longer. and people are then taking that into their spending habits at least in cars. >> reporter: for volkswagen november was rough. sales plunged 24%. largely because dealers could not sell many diesel models that
failed to meet pollution standards. it's unclear when they will have a fix for its diesel engines but until that happens, the german auto brand will likely struggle in the u.s. even as americans buy a record number of new vehicles. phil lebeau, "nightly business report," chicago. while the auto sector seems to be firing on all cylinders, the overall manufacturing sector is not. shrinking in november for the first time in three years. the institute for supply management registered its lowest reading since 2009 and the reasons for that decline are pretty familiar. weakness overseas, low oil prices and the strong dollar. chef executives aren't feeling quite so positive about the economies these days according to a survey of the business roundtable. ceos economic expectations hit the lowest level in three years. this is the third straight decline for that index and as a group, they have lowered their forecast for sales and capital spending over the next six
months. and that decline in business spending was documented in a "wall street journal" article today. a number of recent reports show that companies are not investing as much in things like machines and computers and new buildings. and there's some concern that the weak investment could hold back gains in the economy. jack mcintyre is the portfolio manager with brandi wine global and joins us tonight. nice to have you here. >> nice to be here, sue. >> are you concerned about that, as well, the lack of reinvestment in machines and technology and the like? >> i am because those are the things that add to productivity. and our economy, you know, the productivity component's been missing in action. so this is -- if we can get higher wages but if you get higher productivity, then it doesn't flow through to inflation. if you get higher wages, low productivity, then you actually start to see some inflation pressures. and that's a little bit of a concern. >> can you blame companies for not spending on capital
equipment? >> no. >> because they just don't see the growth there, right? >> yeah, i agree. if i was a ceo, which i'm not, if i was, i'd be worried, too. i think the uncertainty over growth, globally, since the global financial crisis in aggregate, we've had about 23 trillion with a "t" of monetary fiscal stimulus but still in a growth challenged world. washington is certainly overregulating the corporate sector. we're going into this presidential election cycle 37 we've got kind of an anti-businessmen at that time. so there's a list of reasons why the ceos should continue to be uncertain. it is going to have a little bit of a negative drag on the economy. >> has it affected the way that you invest, jack, or look at the bonds and high yield areas that you take a look at every day? >> well, so a couple of things. one is that we know that it's going to have an adverse effect i think on sort of multinationals, on technology.
ibm, honeywell, ge, caterpillar. i think the strong dollar which adds to that uncertainty is going to have a little bit more of a negative impact on the economy than just sort of the uncertainty that ceos have. but it's also i think it is going to slow the economy. we are -- we still own u.s. treasuries. we just see sort of disinflationary pressures, still kind of sort of structural in nature. >> very quickly, you're a ceo and got choose between investing in a new plant or bay paying a nice dividend or buying back shares. what do you do? >> well, i wish i had the confidence to invest in a new plant but i'd probably do the dividend buybacks, m&a, things a little bit more shorter term in nature. >> thanks for joining us tonight. jack mcintyre with brandywine global. >> still ahead, why some drugs for sick patients are out of reach to them when the -- at the time they are needed the most.
♪ house and senate negotiators can agree to a $305 billion five-year highway bill. the legislation funds roads, mass transit programs and it reauthorizes the controversial export/import bank. the bill would be financed in part by surplus federal reserve funds. >> also in washington, a senate investigation says drugmaker gil yad put profits before patients when it priced treatment for hepatitis c drugs at $1,000 per pill. a bipartisan report said the company's own analysis showed making silvaldi less expensive
would allow more to be treated. >> they were fully aware that as the prices kicked up, the number of americans treated and cured would go down. yet, based on our investigation, the company chose to put revenue ahead of affordability, of accessibility for millions of patients. >> the report also showed that medicaid programs spent more than $1 billion before rebates on lvaldi last year to treat fewer than 2.5% of enrollees with the disease. they will now have a more expensive next generation pill called harvoni and says it disagrees with the conclusions. >> the nation's largest pharmacy benefits manager is partnering with a drug company to make a low price alternative to a treatment that costs $750 a pill. the new drug from a so-called compounding firm will be
available to some patients for less than a dollar a pill. it contains the active ingredients in daraprim which gained notoriety when touring it pharmaceuticals can raised its price to $750 a pill. the drug treats a rare parasitic disease. >> express scripts, cvs/caremark and other benefit managers try to keep costs down. to do that, they sometimes have to limit the drugs on approved lists to balance what they refer to as both access and affordability. as bertha coombs reports, that can mean difficult choices for patients. >> the long island breast cancer survivor can't find one with her doctor in network but she's accepted that. >> i'll give up my oncologist and find someone to follow me and as heartbreaking as that is, i'm going to do it. >> she doesn't want to change medications after a bad
experience was a generic, but can't find a plan that covers brand drug famara which costs about $700 a month. >> the goal of that drug is to keep the cancer at bay. it's to suppress the estrogen. we know my cancer was fed by estrogen. so i don't want to play games was that drug into close to one-third here of aca exchange plans limit coverage of cancer and hiv drugs according to a study requiring patients pay up to 40% of the cost of the drugs out of pocket. most employer plans aren't as restrictive, but like narrow doctor networks, brand drug limits are are becoming more common. >> if you can narrow the networks, you can give bigger discounts. we're balancing access and affordable. >> cva and express scripps which negotiate prices for large employees increasingly use their formularies to demand discounts everyone specialty drugmakers. >> if we can't get to the price
we need, we're willing to go exclusive with one company or the other just like we would did with hepatitis. >> express scripps excluded gil yad's $84,000 drug sivaldi to protest its price and only covers the new drug from a rival drugmaker which provided a big discount. that's worrisome to john mali. >> when they start wielding the power and saying you know, we're representing this particular product and not representing any of these other products, before really all the data is in, i think it's a little bit premature. >> mali says most employers stick to express scripps and cvs's formularies. he worries their push for discounts is driving too much of the process. >> i think that col limit access to the right drug for the right person. >> the drug benefit say they put patients and drug effectiveness first but price matters. she thinks they need patients at the negotiating table along with
pharma and pairs. >> let's lock the door, throw away the key and until somebody comes up with some kind of reasonable answer, nobody leaves the room. >> but first, she needs to find a health plan. bertha coombs, "nightly business report," new york. sally pipes joins us now to talk more about pharmacy benefit managers and the issues affecting pricing of specialty drugs in the u.s. she's the president and ceo of the pacific research institute. welcome, good to have you with us. i want to start at a very basic level to make it real clear. what do pbms do, who pays them and how do they make money. >> pbms are administrators for drug benefit plans. their main clients are insurance plans and those companies that are self-insured. but they also pay out claims to the people that they -- the companies that they cover. they develop formularies which are the types of drugs that are available to people who need to use drugs. and they negotiate discounted prices with drug companies for
to try and get lower prices. so they cover about 210 million people in america and there are three major players in the pbm market. >> is that how they got that the power? because it wasn't always this way. but it seems as though there's been so much concentration merging, you know, the smaller players kind of squeezed out. that you have very few players with a lot of power. >> right. exactly. there are three, express scripps is the largest. their main goal and that have cvs/caremark, they want to be the preferred providers for all of these plans. you know, with obamacare, now, the plans and the formularies for drugs are very important part of the plans and what we're finding is under under obamacare exchange plans, a lot of the newer and more innovative drugs are actually not available. that puts people at risk who need the newest and latest drugs. >> so let's say there's an individual such as in the piece we just saw whose been pribed a
branded drug that is not on the formulary of the pharmacy benefit manager that my company happens to use. what do i do then if it's not on there? do i pony up and say okay, i'll pay the full price? do i go for a generic that is on the formulary but may not work for me? do i fight them? what do i do? >> right. well, i guess the first thing would be to try and fight and see if the drug your doctor prescribed could get on the formulary. it means these people who have been prescribed a brand name drug that's not available, they're going to have to, as you say, pony up for the price. in many cases middle income and lower income people can't afford to do that. so it's a real quandary. you have so much power with the pbms now and they've really been negotiating deep discounts. if you take a drug like sivaldi, the express scripps developed a
really deep discount. and so the other two companies which might have better drugs are not available because they're not on the formularies. it hurts the patient and the consumer. >> thank you very much. this is an ongoing story. i'm sure we'll visit you again on it. sally pipes with the pacific research institute. >> thank you. a hedge fund warning sends shares of tara form power surging. that is where we begin tonight's market focus. hedge fund manager david tepper sent out a public letter to tara form power's board accusing the company which is sun edison, the parent company of pushing low grade projects on to tara. shares rose on the disclosure he has a position in the company. the stock was up 32% to $9.15. slumber jay revealing job cuts. that adds to the 20,000 already announce this had year as oil prices continued to plunge. no details yet on the number of layoffs. shares rose 1% to 78.17.
>> johnson control says it expects sales in 2016 to rise 4% helped by strength in its building efficiency and power solutions businesses. the firm also said it expects to complete the spinoff of its automotive business by next october. shares lower by 1% to 45.47. amazon announces that it had its best sales weekend ever for its consumer devices. the online retail giant says it's best selling projects were its fire tablets and tv streaming device. shares up 2% at 679.06. asina retail reported earnings in revenue that topped estimates after the close. the clothing chain owner said it saw strong sales performance in its lane bryant stores. shares rose. during the regular session, it was about 4% high at $11.78. >> puerto rico avoided default making a crucial debt payment. the commonwealth warned its financial position is
deteriorating and it could trigger future defaults. the governor also said he would start taking the extraordinary step of diverting revenue paid on certain bonds to pay for public services. in paris today, global leader ans continued to work on a landmark climate change agreement and today, president obama said he would like to see a deal both ambitious and legally binding. steve sedgwick reports tonight from the climate conference in paris. >> reporter: the key focus on day two of cop-21 client change talks in paris were the closing remarks from president obama at the oecd before he left paris to go back to the united states. the president is negotiating two very thorny issues. on the one hand, geopolitical problems in the middle east. on the other hand, trying to negotiate a successful climate change deal at cop-21. >> what we think it's an agreement where progress paves the way for countries to update their missions targets on a
regular basis. and each nation has the confidence that other nations are meeting their commitments. we seek an agreement that makes sure developing nations have the resources they need to skip the dirty face of development if they're willing to do their part and to make sure the nation's most vulnerable to climate change have resources to an adopt to the impacts we can no longer avoid. >> he' met wet bredder dole gan of turkey emphasizing the partner to de-escalate the tension with russia. that tension having built up post the downing of a russian bomber over turkey within the last week. he also said that president putin he thought understood the process that needed to take place to reach peace and to get an accord with turkey and so they could concentrate on ridding the middle east of isis. in terms of a climate change deal, he said it was a very ambitious deal but the u.s. was playing its part leading from the front, having agreed a deal with china early on in 2014
which he thought laid the basis for a broader agreement here in paris. also seeking to isolate gop opposition saying if the world's scientists got did, world leaders got it and indeed the climate change was very apparent with el nino, he felt that he hopes the republican opposition would understand that this was for the greater good rather than for scoring points against him as the president. this is steve sedgwick,ing for "nightly business report" in coming up, when it rains, california wants to capture that water. so what companies big and small are doing to hold onto the coming el nino storms.
here's what is to watch tomorrow. we will hear from fed chair janet yellen speaking at the economic club in the nation's capital. adp relations its employment report and we also get data on labor productivity and costs and that's what to watch wednesday. in california, it's all about water. more specifically, the lack of it. and what companies big and small are doing to capture it when the coming el nino storms bring much needed rain to the west coast. jane wells has our story. >> reporter: l.a. may be a desert but it still rains once in awhile and when it does, all that storm water runs out into the ocean. it doesn't have to. you could try to keep it. >> ten inches doesn't seem like a lot but if you take it off a million of squares buildings, it's millions of gallons of water. >> david crawford founded an industry which is growing. for one thing, the federal government has new rules
demanding storm runoff be captured and reused to stop contamination of groundwater. but out west, everyone from individuals to cities to big companies now see it as a way to hold onto the delaunch el nainio may bring. >> what's the biggest project you've done so far? >> probably a 6 million gallon hospital, million gallon system at the gates foundation. >> in fresno, for example, rather than spend billions and wait years to build a new dam, the irrigation district is spending $20 million to build nud ponds to capture el nino's rains now. when full, this ponding facility will hold about 1,000 acre feet of water. all of which will trickle down into a mastiff underground aquifer. in the private sector, see guy technology has installed a massive rooftop system to keep as much water as el nino will bring and fit esh it to use for the cooling system or in the company bathroom. >> our real goal was to reduce the demand and have an
environment that we could actually sustain our operation for a long period of time. >> for companies in the business of selling the equipment, rain water catchment is still a small niche but getting bigger. >> over five years when we've been doing rain harvest and really developing our program, we've carried 50 products online, now we carry over 200 products online. >> of course, whether you spend 98 bucks on a rain barrel or hundreds of thousands of dollars on a rooftop system, to get a return on that investment, it needs to rain. for "nightly business report," jane wells, los angeles. today is called giving tuesday and mark zuckerberg and his wife priscilla promised to donate 99% of their facebook shares to charity. that's about $45 billion over the course of their lives. the charitable endeavors will focus on personalized learning, curing disease and connecting people. and finally tonight, one minnesota couple recently dropped a $500,000 check into a salvation army red kettle
outside a grocery store. the donors told the organization they had once relied on discarded food from a local grocery store and they now can afford to help others. and while some still give by check, more and more are turning to crowd funding websites. over the past year, the site go fund me reports that it has raised over $1 billion from more than 60 million donors in nearly 30 countries. >> that's a great story. >> to end on. >> wow. >> that does it for us tonight. i'm sue herara. we want to remind you, this is the time of year your public television station seeks your support. >> thank you for your support. i'm tyler mathison. we'll see you back here tomorrow.
>> if i had a secret as to how you could stop yourself from aging badly and actually turn the clock around and feel younger, wouldn't you like to know it? i'm miranda esmonde-white, and i'm going to share that secret with you today. >> miranda esmonde-white is host of the long-running public television fitness show "classical stretch" and author of the book "aging backwards." miranda has been training professional athletes since creating her own fitness technique 15 years ago. >> as i've aged, and i'm now 78, my body feels like i'm, i don't know, 60. >> people are always commenting on how fit i look, and i say,